Results 71 to 80 of about 264,642 (338)

Elevated numbers of PD-L1 expressing B cells are associated with the development of AIDS-NHL. [PDF]

, 2019
The risk for non-Hodgkin lymphoma (NHL) is markedly increased in persons living with human immunodeficiency virus (HIV) infection, and remains elevated in those on anti-retroviral therapy (cART).
Conti, David V, Cozen, Wendy, Epeldegui, Marta, Guo, Yu, Martínez-Maza, Otoniel, Penichet, Manuel L   +5 more
core  

Immune-derived PD-L1 gene expression defines a subgroup of stage II/III colorectal cancer patients with favorable prognosis that may be harmed by adjuvant chemotherapy [PDF]

, 2016
A recent phase II study of patients with metastatic colorectal carcinoma showed that mismatch repair gene status was predictive of clinical response to PD-1–targeting immune checkpoint blockade.
Allen, Wendy L., Coleman, Helen G., Dunne, Philip D., Johnston, Patrick G., Lawler, Mark, Longley, Daniel B., Loughrey, Maurice, McArt, Darragh G., McDade, Simon, O'Reilly, Paul G., Salto-Tellez, Manuel, Van Schaeybroeck, Sandra   +11 more
core   +1 more source

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?

Frontiers in Immunology, 2017
PD-1–PD-L1 interaction is known to drive T cell dysfunction, which can be blocked by anti-PD-1/PD-L1 antibodies. However, studies have also shown that the function of the PD-1–PD-L1 axis is affected by the complex immunologic regulation network, and some
Zijun Y. Xu-Monette, Mingzhi Zhang, Jianyong Li, Ken H. Young, Ken H. Young   +4 more
doaj   +1 more source

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade

Immunity, Inflammation and Disease, 2021
Introduction Chronic infections lead to the functional exhaustion of T cells. Exhausted T cells are phenotypically differentiated by the surface expression of the immunoinhibitory receptor, such as programmed death‐1 (PD‐1).
Otgontuya Ganbaatar, Satoru Konnai, Tomohiro Okagawa, Yutaro Nojima, Naoya Maekawa, Yoshiki Ichikawa, Atsushi Kobayashi, Tomoyuki Shibahara, Yojiro Yanagawa, Hidetoshi Higuchi, Yukinari Kato, Yasuhiko Suzuki, Shiro Murata, Kazuhiko Ohashi   +13 more
doaj   +1 more source

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. [PDF]

, 2016
Purpose Treatment with pembrolizumab, an anti-programmed death-1 antibody, at 10 mg/kg administered once every 2 weeks, displayed durable antitumor activity in programmed death-ligand 1 (PD-L1) -positive recurrent and/or metastatic (R/M) head and neck ...
Berger, Raanan, Burtness, Barbara, Cheng, Jonathan D, Chow, Laura QM, Chung, Hyun Cheol, Dolled-Filhart, Marisa, Eder, Joseph Paul, Geva, Ravit, Gupta, Shilpa, Haddad, Robert, Kang, Hyunseok, Keam, Bhumsuk, Lee, Se-Hoon, Lin, Chia-Chi, Mahipal, Amit, Mehra, Ranee, Meister, Amy, Muro, Kei, Pathiraja, Kumudu, Seiwert, Tanguy Y, Tahara, Makoto, Weiss, Jared   +21 more
core   +2 more sources

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

The Prognostic and Therapeutic Value of PD-L1 in Glioma

Frontiers in Pharmacology, 2019
Glioma is the most common type of primary brain tumors. After standard treatment regimen (surgical section, radiotherapy and chemotherapy), the average survival time remains merely around 14 months for glioblastoma (grade IV glioma).
Ruo Qiao Chen, Feng Liu, Feng Liu, Xin Yao Qiu, Xin Yao Qiu, Xiao Qian Chen, Xiao Qian Chen   +6 more
doaj   +1 more source

Hantavirus-driven PD-L1/PD-L2 upregulation: An imperfect viral immune evasion mechanism [PDF]

, 2018
Viruses often subvert antiviral immune responses by taking advantage of inhibitory immune signaling. We investigated if hantaviruses use this strategy.
Abdelaziz, Mohammed O., Hofmann, Jörg, Raftery, Martin J., Schönrich, Günther   +3 more
core   +2 more sources

PD-1/PD-L1 inhibitors [PDF]

Current Opinion in Pharmacology, 2015
Tumors may adopt normal physiologic checkpoints for immunomodulation leading to an imbalance between tumor growth and host surveillance. Antibodies targeting the PD-1/PD-L1 checkpoint have shown dynamic and durable tumor regressions, suggesting a rebalancing of the host-tumor interaction.
Janis M. Taube, Joel C. Sunshine
openaire   +3 more sources